Moalife Plus Obtains HACCP Certification for Korean Food Hygiene Management Grade

Moa Life Plus announced that following its acquisition of the Excellent Health Functional Food Manufacturing Practice (GMP) certification in May 2020, it has obtained the Hazard Analysis and Critical Control Points (HACCP) certification on the 10th, enabling the production of even more hygienic and safe products.

The HACCP-certified product is a processed product type of poly-gamma-glutamic acid, Moa Life Plus’s flagship product, with a certification validity period of three years until October 9, 2027.

Moa Life Plus is a research, development, and manufacturing company in the fields of biopharmaceuticals, health functional foods, and food. It possesses foundational technologies such as HumaMax technology and Basic Material (γ-PGA)-based HumaMax technology. In particular, its main product, the poly-gamma-glutamic acid material, has been recognized by the Korea Food & Drug Administration (KFDA) as an individually approved functional ingredient for immune function enhancement under the name ‘Cheonggukjang Bacteria Cultured Extract.’ The company has also registered a patent for an ‘immune-enhancing composition containing poly-gamma-glutamic acid’ with the Korean and Japanese patent offices, entering the health functional food market and launching multiple immune products, thereby pioneering new opportunities in the health functional food sector.

Moa Life Plus stated, “To diversify our health food business, we plan to continuously acquire HACCP certifications for various product types beyond the recently obtained processed product type, building a diverse product lineup. Our uniquely differentiated products will be produced with excellent quality, enhancing consumer trust and contributing to the development of the food business. Moreover, this will secure significant credibility for large-scale exports currently underway, including to China.”

Additionally, following the license agreement signed in May with the U.S. medical aesthetic bio company ELEVAI LABS for two candidate substances for muscle disease treatment, ELEVAI LABS successfully raised $7 million in investment. As a result, Moa Life Plus has received the full $400,000 upfront payment and 950,000 shares as agreed, and expects the Phase 1 clinical trial, anticipated next year, to proceed smoothly.

This content was produced with the assistance of AI translation services.